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ABSTRACT: Cyclic CNGRC (cCNGRC) peptides are very
important targeting ligands for Aminopeptidase N (APN or
CD13), which is overexpressed on the surface of many cancer
cells. In this work we have (1) developed an eﬃcient solid-
phase synthesis and (2) tested on puriﬁed porcine APN and
APN-expressing human cells two diﬀerent classes of cCNGRC
peptides: the ﬁrst carrying a biotin aﬃnity tag or a ﬂuorescent
tag attached to the carboxyl Arg-Cys-COOH terminus and the
second with the tags attached to the amino H2N-Cys-Asn
terminus. Carboxyl-terminus functionalized cCNGRC peptides
3, 6, and 8 showed good aﬃnity for porcine APN and very
good capacity to target and be internalized into APN-expressing cells. In contrast, amino-terminus functionalized cCNGRC
peptides 4, 5, and 7 displayed signiﬁcantly decreased aﬃnity and targeting capacity. These results, which are in agreement with
the recently reported X-ray structure of a cCNGRC peptide bound to APN showing important stabilizing interactions between
the unprotected cCNGRC amino terminus and the APN active site, indicate that the carboxyl and not the amino-terminus of
cCNGRC peptides should be used as a “handle” for the attachment of toxic payloads for therapy or isotopically labeled functions
for imaging and nuclear medicine.
■ INTRODUCTION
Mammalian aminopeptidase N (APN or CD13) is a trans-
membrane zinc-dependent metalloprotease involved in a
variety of processes, including blood pressure regulation, cell
migration, viral uptake, cell survival, and angiogenesis.1 As an
exopeptidase, APN cleaves amino acids from the N-terminal
portion of peptides, preferentially recognizing neutral residues
such as alanine, leucine, and phenylalanine. APN was shown to
be overexpressed in many cancer cells and implicated in tumor
progression and invasion.2 Accordingly, APN knockdown or
inhibition with bestatin 1, a natural substrate analogue, has
been shown to signiﬁcantly impair tumor growth in animal
models.2,3 APN is selectively recognized by peptides containing
the Asn-Gly-Arg (NGR) sequence, a tumor-homing motif
discovered by phage display technologies.4,5 Owing to their
tumor-homing properties, NGR-containing peptides, such as
the cCNGRC 2 (Figure 1), have been conjugated to anticancer
drugs to generate tumor-targeted therapeutics with enhanced
eﬃcacy and reduced oﬀ-target toxicity.5,6 A noteworthy
example is the NGR-TNF-α construct, a tumor-targeted
bioconjugate consisting of human tumor necrosis factor α
fused to the C-terminus of cCNGRC, which is currently
undergoing clinical trials for the treatment of advanced solid
tumors either as a single agent or in combination with standard
chemotherapy (www.clinicaltrials.gov).6,7 The tumor-homing
peptide cCNGRC has also been used in molecular imaging
probes for in vivo detection of APN expression in solid tumors.
Various NGR peptides have been conjugated with signaling
molecules for optical imaging,8 MRI,9 and nuclear imaging
techniques,10 and the ﬁnal constructs tested in tumor xenograft
models.
Despite the potential of APN-directed tumor-homing
strategies, the exact structural requirements necessary for
APN-NGR recognition and tumor targeting with NGR
peptides are still not completely clear. The crystal structure
of porcine APN (which shares a high grade of homology with
human APN) complexed with the c(CNGRC)G peptide has
recently been reported, revealing important structural informa-
tion for the development of high-aﬃnity NGR analogues, as
well as for the rational design of NGR-based bioconjugates used
for site-directed delivery of anticancer drugs and cancer imaging
agents.11 X-ray crystallographic data showed that the NGR
motif binds to the zinc-aminopeptidase active site forming
speciﬁc interactions through the side chains of asparagine and
arginine. The binding mode of the cyclic cCNGRC resembles
that of APN natural substrates,12 although not surprisingly the
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presumed scissile peptide bond within the cCNGRC backbone
was found to be stable against enzymatic hydrolysis (Figure 1).
Importantly, the N-terminal amino group of APN natural
substrates and inhibitors, such as polyalanine and bestatin 1
(Figure 1), was shown to play a crucial role in the binding
process, forming strong interactions with a negatively charged
region of the APN catalytic site. X-ray data showed that the
H2N-Cys-Asn fragment of the cCNGRC peptide strongly
overlaps with the N-terminal H2N-Ala-Ala in APN-bound
polyalanine,11,12 whereas the carboxyl terminus on the second
cysteine appears to play a less important role in the binding to
APN.
Based on the structural data above, we hypothesized that the
carboxyl and not the amino-terminus should be used as a
functional “handle” for the synthesis of cCNGRC-bioconju-
gates, and that the N-terminus should remain in unprotected
NH2-form. Surprisingly, this key aspect has never beento the
best of our knowledgediscussed in the literature, where a
wide structural range of linear or cyclic NGR peptides has been
reported with variable degree of success. In particular, both the
N-terminus10,13−17 and C-terminus4,6 of cCNGRC have been
used as “handles” for bioconjugation, with or without
protection of the unused “handle”,13 apparently without a
rational structural design.4,10 The aim of this study was to shed
light on the role of carboxyl and amino “handles” of cCNGRC
constructs in the APN targeting process and also to provide a
structural rationale for the design of APN-targeted cCNGRC
bioconjugates. To this end, we synthesized a series of cCNGRC
derivatives (3−7, Table 1) where either the C-terminus or the
N-terminus were modiﬁed by amidation, acetylation, or
conjugation with a biotinylated molecular fragment. The eﬀect
of these modiﬁcations on the capacity of derivatives 3−7 to
inhibit the enzymatic activity of APN was investigated, clearly
showing that the N-terminus is unsuitable as a handle for
bioconjugation and should be present in unprotected NH2
form. Conversely, the C-terminus was identiﬁed as the optimal
attachment site for the development of cCNGRC-based
derivatives targeting APN. Finally, a ﬂuorescent cCNGRC-
based probe (8), consisting of Oregon green 488 (OG) fused
through a lysine linker with the C-terminus of cCNGRC, was
synthesized and successfully used for imaging of APN
expression on human HT1080 cells.
■ RESULTS AND DISCUSSION
Synthesis. The following structural modiﬁcations were
introduced on the cCNGRC peptide 2: (i) the terminal COOH
group was substituted by a CONH2 (3); (ii) the N-terminus
was masked by acetylation (4); (iii) the N- or C-terminus were
conjugated to a biotinylated function to give derivatives 5 and
6, respectively; (iv) compound 6 was further modiﬁed by N-
terminus acetylation (to give derivative 7). Finally, compound 8
was designed like 6 but with a ﬂuorescent tag (Oregon Green
488) replacing the biotinylated function on the C-terminus.
Molecules 2−8 were prepared via solid-phase peptide synthesis
(SPPS) using the Fmoc strategy. Peptides functionalized on the
N-terminus and displaying a free C-terminus (2, 4, and 5) were
assembled on a Fmoc-Cys acetamidomethyl (Acm) preloaded
Wang resin. The Fmoc-protected amino acids were coupled in
sequence using HATU as a coupling agent (Scheme 1).
Biotinylated conjugate 5 was obtained by linking the biotin
moiety to the CNGRC peptide through 6-aminohexanoic acid
(ε-Ahx) as a spacer arm. Cyclization of the linear ε-Ahx-
CNGRC precursor on-resin by forming a disulﬁde bridge via
iodine-mediated oxidation of the thiol groups followed by
biotinylation aﬀorded peptide 5, albeit in low yields. Cleavage
and subsequent cyclization of the precursor 9 and its acetylated
derivative in solution phase gave the desired products 2 and 4,
respectively, in slightly better yields. In order to optimize the
cyclization step, compound 3 (Scheme 2) was prepared
following a diﬀerent synthetic approach. The acid-labile trityl
(Trt) group, which can be removed simultaneously with the
cleavage of the linear precursors from the resin, was used as
cysteine S-protecting group.
Figure 1. Structures of the APN natural substrate polyalanine, APN
inhibitor bestatin 1, and cCNGRC tumor-homing peptide 2 (crystal
structure of the APN catalytic site in complex with cCNGRCG, PDB
code 4OU3). The NH2 functions of polyalanine and bestatin
recognized by APN as the N-terminal portion of peptides are colored
in red.
Table 1. Structures and ESI-MS of Peptides 2−8
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Peptide 3 was assembled on a Rink resin and the Fmoc-
protected amino acids were coupled in sequence using HATU
as a coupling agent (Scheme 2). After cleavage of the linear
precursor 10 from the resin, the cyclization step was
accomplished in solution phase in less than 15 min by adding
N-chlorosuccinimide (NCS) as an oxidizing agent, according to
a procedure reported in the literature.18 A similar strategy
based on the use of the acid-labile p-methoxytrityl (Mmt) as
cysteine S-protecting groupwas then exploited for conjugates
6−8 which were synthesized on a Rink solid support (Scheme
3). Assembly of the CNGRC sequence was performed after
loading the resin with Fmoc-Gly-OH and coupling with Fmoc-
Lys(Dde)-OH. Once the last amino acid of the heptapeptide
sequence (11) was added, the orthogonal protecting group of
lysine (Dde) was removed with hydrazine and conjugation with
biotin or 5(6)-carboxy-2′,7′-diﬂuoroﬂuorescein (Oregon green
488)which was freshly synthesized19 and used as a mixture of
5- and 6-regioisomerswas accomplished on-resin through the
amino function of the lysine side-chain to give intermediates 12
and 13, respectively. For achieving an orthogonal protection
between the lysine side chain and the N-terminal group of
peptide 11, the last amino acid added to the sequence was
protected as N-Boc derivative (Boc-Cys(Mmt)-OH). The
Fmoc protecting group is, in fact, cleaved simultaneously with
Dde upon treatment with hydrazine. Precursor 13 was cleaved
from the solid support and the desired conjugate 8 was
obtained performing the cyclization step in solution phase using
NCS. On the other hand, after cleavage of the biotinylated
precursor 12 from the resin, conjugates 6 and 7 were prepared
forming the disulﬁde bond by air oxidation. (Note: Treatment
of biotinylated linear peptides with NCS resulted in a mixture
of undesired byproducts, probably because the biotin moiety
does not tolerate strong oxidation conditions.)
APN Inhibition Assay. Peptide 2 and its derivatives 3−7
were examined for their inhibitory activity toward porcine APN
using a spectrophotometric assay commonly employed for
screening APN inhibitors.12,20,21 Brieﬂy, APN and the substrate
L-leucine-p-nitroanilide were incubated for 1 h in the presence
of gradient concentrations of peptides 2−7 and formation of
the product p-nitroaniline was measured reading absorbance at
405 nm. Bestatin 1, a potent APN inhibitor, was included in the
assay as a positive control, while biotin was used as a negative
one. The results of the assay are summarized in Table 2 and in
Figure 2, which show the eﬀects of C- or N-terminus
functionalization on the activity of cCNGRC 2. In accordance
with data previously reported,20 the inhibitory potency of
cCNGRC 2 was considerably lower than that of 1 (about 120-
fold, Table 2). Replacement of the C-terminus COOH of 2
with a CONH2 function (derivative 3) had negligible eﬀect on
the inhibitory potency of the parent peptide (Table 2 and
Figure 2a,b). Conversely, the activity was markedly impaired
upon N-terminus acetylation (compound 4) or by conjugation
Scheme 1. Synthesis of Derivatives 2, 4, and 5a
aReagents and conditions: SPPS Fmoc strategy: (Fmoc cleavage) 20%
piperidine in DMF, rt, 10 min; (coupling) Fmoc-amino acid, HATU,
DIPEA, DMF, rt, 2 h. Sequence of addition: Fmoc-Arg(Pbf)-OH,
Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys(Acm)-OH. (a) TFA/
TIPS/H2O 95:2.5:2.5, rt, 2 h; (b) I2, AcOH, HCl, rt, 2 h; (c) DCM/
Acetic Anhydride/DIPEA 20:4:1, rt, 1 h; (d) (i) Fmoc-ε-Ahx-OH,
DIC, Oxyma Pure, DMF, rt, 2 h; (ii) 20% piperidine in DMF, rt, 10
min; (e) I2, DMF/H2O 4:1, rt, 4 h; (f) biotin, DIC, Oxyma Pure,
DMF, rt, 24 h.
Scheme 2. Synthesis of 3a
aReagents and conditions: SPPS Fmoc strategy: (Fmoc cleavage) 20%
piperidine in DMF, rt, 10 min; (coupling) Fmoc-amino acid, HATU,
DIPEA, DMF, rt, 2 h. Sequence of addition: Fmoc-Cys(Trt)-OH,
Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys-
(Trt)-OH; (a) TFA/TIPS/H2O 95:2.5:2.5, rt, 2 h; (b) NCS, H2O, rt,
15 min.
Scheme 3. Synthesis of Conjugates 6−8a
aReagents and conditions: SPPS Fmoc strategy: (Fmoc cleavage) 20%
piperidine in DMF, rt, 10 min; (coupling) Fmoc-amino acid, HATU,
DIPEA, DMF, rt, 2 h. Sequence of addition: Fmoc-Gly-OH, Fmoc-
Lys(Dde)-OH, Fmoc-Cys(Mmt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-
Gly-OH, Fmoc-Asn(Trt)-OH, Boc-Cys(Mmt)-OH; (a) 2%
NH2NH2 in DMF, rt, 3 min; (b) biotin, HATU, DIPEA, DMF, rt, 2
h; (c) Oregon green 488, HATU, DIPEA, DMF, rt, 2 h; (d) TFA/
TIPS/H2O 95:2.5:2.5, rt, 2 h; (e) atmospheric O2, 50 mM PB, pH 7.4,
rt, 72 h; (f) NCS, H2O/CH3CN 9:1, rt, 15 min; (g) acetic anhydride,
H2O, rt, 10 min.
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of this function to a biotinylated linker (compound 5). As
shown in Figure 2a, at a concentration of 1.25 mM of peptides
4 and 5 the inhibition of APN activity was less than 30%.
Interestingly, bioconjugate 6 (consisting of biotin fused through
a lysine linker to the C-terminus of cCNGRC 2) showed an
increased inhibitory potency relative to the parent peptide 2
(almost 15-fold, Table 2). The latter result is in accordance
with the IC50 value of 38.7 μM reported in the literature
11 for
the c(CNGRC)G peptide, suggesting that an additional amino
acid directly linked to the C-terminus of cCNGRC peptides can
lead to an increase of APN inhibitory potency. Similarly to what
was previously observed with the N-acetylated derivative 4,
acetylation of the free N-terminus signiﬁcantly impaired the
activity of the resulting C-biotinylated compound 7 (Figure
2a,c). Overall, these results show that the C-terminus is the
optimal “handle” for cCNGRC peptides derivatization, whereas
the N-terminus must remain in free NH2 form for achieving
higher APN inhibitory activity.
APN Inhibition Assay on HT1080 Cells. To further
conﬁrm these results in a more physiological system, we
measured the inhibitory activities of C-derivatives 3 and 6 and
the corresponding N-acetylated derivatives 4 and 7 toward
human APN expressed on the surface of living cells. We
selected the human ﬁbrosarcoma cell line (HT1080) which is
known to express high levels of APN and has been extensively
used to measure human APN activity. Adherent HT1080 cells
and the substrate L-leucine-p-nitroanilide were incubated for 1 h
in the presence of gradient concentrations of inhibitors and
formation of the product p-nitroaniline was measured on a
plate reader at 405 nm. Bestatin 1 was included in the test as a
positive control. As shown in Figure 2d, the inhibitory activities
of the tested compounds exactly replicated the results obtained
with the puriﬁed enzyme. The N-acetylated derivative 4 showed
reduced activity compared to 3, while the C-biotinylated 6
displayed the highest inhibitory potency of the series. The
activity of the N-acetylated derivative 7 was signiﬁcantly
reduced, in complete agreement with the results previously
obtained with the puriﬁed enzyme.
Imaging of APN in HT1080 Cells with cCNGRCKG-OG
Bioconjugate 8. A cCNGRC peptide carrying a ﬂuorescent
moiety at the C-terminus cCNGRCKG-OG 8 was then used to
image APN in living cells. Oregon green was selected as
ﬂuorescent probe because its high quantum eﬃciency and
resistance to photobleaching make it a good and ﬂexible tool
for both wide-ﬁeld and confocal imaging.19 To decide the best
concentration for APN detection on HT1080, cells were
incubated at 0 °C for 1 h, then ﬁxed and imaged under a
ﬂuorescent microscope at 20× magniﬁcation. We found that
the ﬂuorescent signal was saturable and approached the
maximum with a cCNGRCKG-OG 8 concentration of 100
μM (Figure 3a,b). More importantly the binding of the
ﬂuorescent probe was greatly reduced in the presence of
bestatin 1 (100 μM) or cCNGRCKG-biotin 6 (1 mM),
conﬁrming that the binding is indeed through APN (Figure 3c).
It has been shown that APN is rapidly internalized after binding
on the cell surface.22 The internalization is fundamental for
some of the APN functions and is exploited by some
coronavirus to enter and infect epithelial cells.23 In addition,
APN internalization has been used to speciﬁcally target cancer
cells with NGR conjugated to cytotoxic agents. We therefore
analyzed the ability of the ﬂuorescent probe 8 to undergo APN-
mediated endocytosis. As shown in Figure 3d the ﬂuorescent
conjugate 8 is fully internalized and present in intracellular
vesicles after 1 h at 37 °C.
■ CONCLUSIONS
This study paves the way for a more rational use of cCNGRC
peptides as targeting vectors in therapy and imaging. First of all,
we have developed an eﬃcient solid-phase synthesis of
cCNGRC peptides and conjugates carrying diﬀerent functional
tags on either the amino- or the carboxyl-terminus, which could
be prepared on a scale of hundreds of milligrams. In agreement
with the recently reported X-ray structure of a cCNGRC
peptide bound to porcine APN,11 we have shown that the
optimal conjugation siteor “handle”for linkers carrying a
biotin aﬃnity tag or a ﬂuorescent moiety is the Arg-Cys-COOH
C-terminus, which preserves the capacity of CNGRC peptides
to bind and inhibit APN. Conversely, the H2N-Cys-Asn N-
terminus must be present in free form as it appears to be
involved in key interactions with the APN active site. Since (1)
the porcine APN residues involved in the binding to cCNGRC
peptides are completely conserved between human and porcine
APNs, and (2) APN inhibitory activity of peptides 3−7 and cell
internalization capacity of 8 were also conﬁrmed on human
cells, these results should be translatable to the development of
more eﬃcient cCNGRC constructs, conjugates, and theranos-
Table 2. IC50 Values of Bestatin 1 and NGR Peptides 2−7
a
compound IC50(μM)
Bestatin 1 5.1
2 636
3 620
4 >1000
5 >1000
6 43.3
7 >1000
aIC50 values were calculated from concentration−response curves by a
nonlinear regression analysis using GraphPad Prism Software.
Figure 2. (a) Eﬀect of bestatin 1 (25 μM), biotin (1.25 mM), and
peptides 2−7 (1.25 mM) on the enzymatic activity of APN. The
results are expressed as percentage of APN residual activity relative to
the catalytic activity of APN in the absence of any inhibitor taken as
100%; (b) inhibition of APN by peptides 2 and 3; (c) inhibition of
APN by peptides 4, 6, and 7; (a−c) data are the average of two
independent experiments performed in duplicate, with error bars
displaying standard deviations; (d) inhibition of APN expressed on
HT1080 cells by bestatin 1 (25 μM) and NGR inhibitors (1.25 mM).
The results are expressed as percentage of APN residual activity
relative to the untreated control (100%). The data are the average of
three replicates with error bars displaying standard deviations.
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.6b00136
Bioconjugate Chem. 2016, 27, 1332−1340
1335
tics carrying toxic payloads or radioisotopes for preclinical and
clinical use.
■ EXPERIMENTAL PROCEDURES
1H NMR, 13C NMR, and 19F NMR spectra were recorded on a
Bruker AVANCE III 400 NMR spectrometer. Chemical shifts
(δ) are reported in parts per million (ppm) and coupling
constants (J) are given in Hertz (Hz). The abbreviations s, d,
dd, t, m, and brs stand for singlet, doublet, doublet of doublets,
triplet, multiplet, and broad singlet, in that order. All 13C NMR
spectra were proton decoupled. Mass analyses were performed
using Agilent 1200 HPLC system coupled to Agilent G6120
single quadrupole detector equipped with an electrospray
ionization (ESI) source in direct infusion modality. ESI-MS
spectra were recorded in positive mode. RP (reverse phase)
HPLC-MS analyses were performed with an Agilent 1200
HPLC system equipped with a DAD and an ESI-MS detector.
HPLC conditions for analytical analyses: Phenomenex Luna
C18 column, 5 μm, 100 Å, 250 × 4.6 mm (L × ID), inj. volume
20 μL, ﬂow rate 1 mL/min. HPLC conditions for semi-
preparative puriﬁcation: Phenomenex Luna C18 column, 5 μm,
100 Å, 250 × 10.0 mm (L × ID), ﬂow rate 5 mL/min. The
amount of TFA in the puriﬁed peptides was quantiﬁed by 19F
NMR using 2,4-dinitro-ﬂuorobenzene as an internal standard.
Synthesis of cCNGRC 2. Fmoc-Cys(Acm) Wang resin
(500 mg, 0.30 mmol, loading: 0.60 mmol/g) was swollen in
DCM for 30 min and then washed with DMF. Fmoc cleavage
was carried out using 20% piperidine in DMF, at rt for 10 min
(×2). The resin was washed with DMF (3 × 5 mL) and DCM
(3 × 5 mL). The coupling reaction was performed by adding to
the resin a solution of the Fmoc-amino acid (1.5 mmol, 5
equiv), HATU (560 mg, 1.47 mmol, 4.9 equiv), DIPEA (0.51
mL, 3.0 mmol, 10 equiv) in DMF (5 mL), and the mixture was
shaken for 2 h. The coupling sequence was: Fmoc-Arg(Pbf)-
OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys(Acm)-
OH. Once the linear pentapeptide was assembled, the N-
terminal Fmoc protecting group vas removed. Cleavage of the
pentapeptide from the resin and simultaneous removal of Trt
and Pbf protecting groups was performed using a mixture of
TFA/TIPS/H2O 95:2.5:2.5 v/v/v for 2 h. The cleavage mixture
was drained oﬀ and the resin washed with TFA and DCM. The
mixture was concentrated and Et2O was added to precipitate
the crude peptide. The crude linear peptide (270 mg, 0.30
mmol, 1 equiv) was dissolved in AcOH (15 mL) and added
dropwise over 3 h to a solution of I2 (0.12 M) in AcOH (150
mL) and HCl 10 M (1 mL).24 The cyclization reaction was
monitored by RP-HPLC coupled to tandem ESI-MS and
stopped after 2 h by adding Et2O. The resulting suspension was
cooled in dry ice and then centrifuged at 5000 rpm for 3 min,
decanted, and the resulting white solid was puriﬁed by
semipreparative RP-HPLC (Solvent A: CH3CN 0.1% TFA,
Solvent B: H2O 0.1% TFA, gradient: from 1% to 7% of A in 8
min, ﬂow 5 mL/min, tR = 6 min). The puriﬁed compound was
lyophilized and obtained as a white powder (35 mg, 2·TFA salt,
15% yield based on the estimated loading of the resin). 1H
NMR (400 MHz, D2O): δ = 4.92 (t, J = 7.2 Hz, 1H), 4.64 (dd,
J = 9.9, 3.5 Hz, 1H), 4.31 (t, J = 7.3 Hz, 1H), 4.24−4.08 (m,
2H), 3.67 (d, J = 15.6 Hz, 1H), 3.40−3.26 (m, 3H), 3.23 (t, J =
6.7 Hz, 2H), 3.12 (dd, J = 14.4, 9.9 Hz, 1H), 2.84 (dd, J = 15.3,
6.5 Hz, 1H), 2.72 (dd, J = 15.5, 8.0 Hz, 1H), 1.91−1.61 (m,
4H). 13C NMR (101 MHz, D2O, the signal of TFA was not
included): δ = 174.20, 173.81, 173.68, 171.57, 170.60, 167.26,
156.74, 53.61, 52.73 (one signal for two carbons, as detected by
HSQC analysis), 50.07, 42.43, 41.18, 40.49, 40.43, 36.14, 27.22,
24.21. MS (ESI, m/z): calculated for C18H31N9O7S2 549.18;
found 550.2 [M + H]+. RP-HPLC: solvent A: CH3CN 0.1%
TFA, Solvent B: H2O 0.1% TFA, gradient: from 1% to 15% of
A in 15 min, tR = 7.6 min, ﬂow: 1 mL/min, λ = 220 nm.
Synthesis of cCNGRC−CONH2 3. Fmoc protected Rink
Amide MBHA resin HL (1.0 g, 0.87 mmol, loading: 0.87
mmol/g) was used for this synthesis. Swelling, Fmoc cleavage
and washing procedures were performed as described above for
compound 2. The coupling reactions were accomplished by
adding to the resin a solution of the Fmoc-amino acid (1.74
mmol, 2 equiv), HATU (650 mg, 1.70 mmol, 1.96 equiv),
DIPEA (0.6 mL, 3.48 mmol, 4 equiv) in DMF (5 mL) and
shaking the mixture for 2 h. The amino acid coupling sequence
was as follows: Fmoc-Cys(Trt)-OH, Fmoc-Arg(Pbf)-OH,
Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, and Fmoc-Cys(Trt)-OH.
Cleavage of the pentapeptide from the resin and simultaneous
removal of Trt and Pbf protecting groups was performed using
a mixture of TFA/TIPS/H2O 95:2.5:2.5 v/v/v for 2 h. The
mixture was concentrated and Et2O was added to precipitate
the crude peptide. N-Chlorosuccinimide (60 mg, 0.45 mmol, 1
equiv) was added to the solution of the crude linear peptide
(350 mg, 2·TFA salt, 0.45 mmol, 1 equiv) in H2O (20 mL) and
the reaction was allowed to stir at room temperature for 15
min. The reaction mixture was then frozen in dry ice and
freeze−dried to obtain the crude cyclic peptide as a white
Figure 3. Tracer binding studies of cCNGRCKG-OG 8 on HT1080
cells. (a) Binding curve of cCNGRCKG-OG 8 on HT1080 human
ﬁbrosarcoma cells. (b) Incubation with tracer 8 shows binding to
HT1080 cells. (c) Quantiﬁcation of the ﬂuorescent signal present in
the cells showing that the binding of ﬂuorescent probe 8 to HT1080
cells is eﬀectively inhibited by coincubation with bestatin (100 μM)
and cCNGRCKG-biotin 6 (1 mM). (d) Internalization of the probe 8
via APN-mediated endocytosis.
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powder. The crude peptide was puriﬁed by semipreparative RP-
HPLC (Solvent A: CH3CN 0.1% TFA, Solvent B: H2O 0.1%
TFA, gradient: from 1% to 7% of A in 7 min, ﬂow: 5 mL/min,
tR = 6.2 min) and lyophilized to give compound 3 as a white
powder (170 mg, TFA salt, 25% yield based on the estimated
loading of the resin). 1H NMR (400 MHz, D2O): δ = 4.92 (t, J
= 7.3 Hz, 1H), 4.63 (dd, J = 10.4, 3.4 Hz, 1H), 4.31 (t, J = 7.3
Hz, 1H), 4.20−4.13 (m, 2H), 3.67 (d, J = 15.7 Hz, 1H), 3.38
(dd, J = 14.5, 6.8 Hz, 1H), 3.32 (dd, J = 14.5, 3.5 Hz, 1H),
3.27−3.18 (m, 3H), 3.05 (dd, J = 14.5, 10.4 Hz, 1H), 2.85 (dd,
J = 15.5, 6.7 Hz, 1H), 2.73 (dd, J = 15.5, 7.9 Hz, 1H), 1.94−
1.57 (m, 4H). 13C NMR (101 MHz, D2O, the signal of TFA
was not included): δ = 174.24, 174.21, 173.97, 171.62, 170.70,
167.23, 156.74, 53.50, 52.84, 52.69, 50.08, 42.40, 41.18, 40.51,
40.44, 36.03, 27.04, 24.27. MS (ESI, m/z): calculated for
C18H32N10O6S2 548.19; found 549.2 [M + H]
+. RP-HPLC:
solvent A: CH3CN 0.1% TFA, Solvent B: H2O 0.1% TFA,
gradient: from 1% to 15% of A in 15 min, tR = 8.0 min, ﬂow: 1
mL/min, λ = 220 nm.
Synthesis of Ac-cCNGRC 4. The linear precursor 9
(Scheme 1) was assembled on the Fmoc-Cys(Acm) preloaded
Wang resin (500 mg, 0.30 mmol, loading: 0.60 mmol/g)
following the procedure described for compound 2. After Fmoc
cleavage from the last amino acid, acetylation of the N-terminus
was performed on-resin adding a solution of DCM/acetic
anhydride/DIPEA 20:4:1 v/v/v (8 mL) and the resulting
suspension was shaken for 1 h (repeated 2 times). Cleavage
from the resin was carried out using a solution of TFA/TIPS/
H2O 95:2.5:2.5 v/v/v for 2 h. The mixture was concentrated
and Et2O was added to precipitate the crude peptide.
Cyclization was performed following the procedure described
for 2.24The crude material was puriﬁed by semipreparative RP-
HPLC (Solvent A: CH3CN 0.1% TFA, Solvent B: H2O 0.1%
TFA, gradient: from 10% to 15% of A in 7 min, ﬂow: 5 mL/
min, tR = 5.7 min) and lyophilized to give compound 4 as a
white powder (65 mg, TFA salt, 30% yield based on the
estimated loading of the resin). 1H NMR (400 MHz, D2O): δ =
4.74 (dd, J = 9.0, 3.6 Hz, 1H), 4.65 (t, J = 7.2 Hz, 1H), 4.49−
4.39 (m, 2H), 4.22 (d, J = 16.4 Hz, 1H), 3.73 (d, J = 16.4 Hz,
1H), 3.33 (dd, J = 15.3, 4.4 Hz, 1H), 3.25 (t, J = 6.6 Hz, 2H),
3.21−3.18 (m, 1H), 3.15 (dd, J = 7.3, 3.8 Hz, 2H), 2.93 (dd, J =
15.4, 6.6 Hz, 1H), 2.71 (dd, J = 15.4, 7.7 Hz, 1H), 2.05 (s, 3H),
2.00−1.62 (m, 4H). 13C NMR (101 MHz, D2O, the signal of
TFA was not included): δ = 174.78, 174.39, 173.51, 173.41,
172.18, 172.02, 171.24, 156.73, 53.69, 53.39, 52.60, 50.61,
42.60, 40.96, 40.54, 40.47, 35.57, 27.59, 24.31, 21.74. MS (ESI,
m/z): calculated for C20H33N9O8S2 591.19 found 592.2 [M +
H]+. RP-HPLC: solvent A: CH3CN 0.1% TFA, Solvent B: H2O
0.1% TFA, gradient: from 10% to 25% of A in 11 min tR = 6.7
min, ﬂow 1 mL/min, λ = 220 nm.
Synthesis of Biotin-ε-Ahx-cCNGRC 5. The linear
precursor 9 (Scheme 1) was assembled on the Fmoc-
Cys(Acm) preloaded Wang resin (100−200 mesh, 200 mg,
0.14 mmol, loading: 0.70 mmol/g) following the procedure
described for compound 2. After Fmoc cleavage from the last
amino acid, a solution of Fmoc-ε-Ahx-OH (250 mg, 0.70 mmol,
5 equiv), DIC (0.11 mL, 0.70 mmol, 5 equiv), and Oxyma Pure
Novabiochem (100 mg, 0.70 mmol, 5 equiv) in DMF (3 mL)
was added and the suspension was shaken for 2 h. Then, the N-
terminal Fmoc protecting group was removed. The cyclization
step was carried out on resin by adding to the resin a solution
of I2 (350 mg, 1.4 mmol, 10 equiv) in DMF/H2O 4/1 (v/v) (3
mL). After 4 h the solvent was removed and the resin was
extensively washed with DMF (2 × 5 mL), 2% ascorbic acid in
DMF (2 × 5 mL), DMF (5 × 5 mL), and DCM (3 × 5 mL).
Biotin (340 mg, 1.4 mmol, 10 equiv), DIC (0.22 mL, 1.4 mmol,
10 equiv), and Oxyma Pure Novabiochem (200 mg, 1.4 mmol,
10 equiv) were suspended in DMF (14 mL) at 60 °C and
stirred for about 40 min until the activated biotin was
completely dissolved. After cooling to room temperature, the
reaction mixture was added to the cyclic peptide-resin and
shaken for 24 h. The resin was washed with DCM (5 × 10 mL)
and DMF (5 × 10 mL). Biotin-labeled cyclic peptide was
cleaved from the resin, along with the deprotection of the
amino acid side chains by adding a mixture of TFA/TIPS/H2O
95/2.5/2.5 (v/v/v) for 2 h. The mixture was concentrated and
Et2O was added to precipitate the crude peptide. The crude was
dissolved in H2O, puriﬁed by semipreparative RP-HPLC
(Solvent A: CH3CN 0.1% TFA, Solvent B: H2O 0.1% TFA,
gradient: from 10% to 35% of A in 15 min, ﬂow 5 mL/min, tR =
7 min) and lyophilized to give compound 5 as a white powder
(9.6 mg, TFA salt, 7% yield based on estimated loading of the
resin). 1H NMR (400 MHz, D2O): δ = 4.66−4.57 (m, 2H),
4.50 (dd, J = 8.4, 5.9 Hz, 1H), 4.46−4.35 (m, 2H), 4.22 (d, J =
16.3 Hz, 1H), 4.00−3.96 (m, 1H), 3.72 (d, J = 16.4 Hz, 1H),
3.39−2.77 (m, 12H), 2.71 (dd, J = 15.5, 7.5 Hz, 1H), 2.40−
2.23 (m, 4H), 1.96−1.30 (m, 16H). MS (ESI, m/z): calculated
for C34H56N12O10S3 888.34; found 889.3 [M + H]
+. RP-HPLC:
solvent A: CH3CN 0.1% TFA, Solvent B: H2O 0.1% TFA,
gradient: from 5% to 50% of A in 15 min, tR = 10.46 min, ﬂow:
1 mL/min, λ = 220 nm.
Synthesis of cCNGRCKG-biotin 6. The linear peptide 11
was assembled on an Fmoc protected Rink Amide MBHA resin
HL (1.0 g, 0.87 mmol, loading: 0.87 mmol/g) following the
procedure already described for compound 3. The amino acid
coupling sequence was Fmoc-Gly-OH, Fmoc-Lys(Dde)-OH,
Fmoc-Cys(Mmt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH,
Fmoc-Asn(Trt)-OH, Boc-Cys(Mmt)-OH. Once the linear
heptapeptide 11 was assembled, Dde removal was achieved
using a solution (10 mL) of NH2NH2 (2%) in DMF for 3 min
(×2). Biotin (420 mg, 1.74 mmol, 2 equiv) was dissolved in
DMF (8 mL) and the solution warmed at 80 °C in order to
solubilize the solid powder. Once biotin was completely
solubilized, the mixture was cooled to rt before adding
HATU (650 mg, 1.70 mmol, 1.96 equiv) and DIPEA (0.6
mL, 3.48 mmol, 4 equiv). The mixture was added to the resin
and the suspension was shaken for 2 h. The coupling was
repeated two times. Cleavage of the biotin labeled peptide 12
from the resin and simultaneous removal of Mmt, Trt, and Pbf
protecting groups was performed using a mixture of TFA/
TIPS/H2O 95:2.5:2.5 v/v/v for 2 h. The mixture was
concentrated and Et2O was added to precipitate the crude
peptide. The crude peptide (860 mg, 0.72 mmol) was dissolved
in 50 mM phosphate buﬀer, pH 7.4 (250 mL) and the reaction
was stirred while bubbling air through it. The disulﬁde bridge
formation was monitored by RP-HPLC coupled to tandem
ESI-MS and it was complete after 72 h. The aqueous medium
was concentrated under reduced pressure and the resulting
precipitate was ﬁltered and washed several times with H2O and
CH3CN. Compound 6 was obtained as a pure white powder
400 mg, 48% yield, based on the estimated loading of the
resin). 1H NMR (400 MHz, D2O): δ = 4.79 (overlapped with
solvent signal as detected by COSY and HSQC experiments,
1H) 4.66−4.59 (m, 2H), 4.44 (dd, J = 7.7, 4.5 Hz, 1H), 4.40−
4.34 (m, 1H), 4.31 (dd, J = 8.4, 5.5 Hz, 1H), 4.15 (d, J = 16.0
Hz, 1H), 3.96 (d, J = 17.1 Hz, 1H), 3.90 (d, J = 17.1 Hz, 1H),
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3.75 (d, J = 16.2 Hz, 1H), 3.70 (brs, 1H), 3.40−2.73 (m, 13H),
2.27 (t, J = 7.0 Hz, 2H), 1.96−1.30 (m, 16H). MS (ESI, m/z):
calculated for C36H61N15O10S3 959.39; found ESI-MS: m/z
960.3 [M + H]+. RP-HPLC: solvent A: CH3CN 0.1% TFA,
Solvent B: H2O 0.1% TFA, gradient: from 5% to 40% of A in
11 min, tR = 8.2 min, ﬂow: 1 mL/min, λ = 220 nm.
Synthesis of Ac-cCNGRCKG-biotin 7. Compound 6 (15
mg, 15.6 μmol, 1 equiv) was dissolved in water (2.5 mL) and
treated with acetic anhydride (5.0 μL, 52.9 μmol, 3.4 equiv) at
rt for 10 min. The crude peptide was puriﬁed by semi-
preparative RP-HPLC (Solvent A: CH3CN 0.1% TFA, Solvent
B: H2O 0.1% TFA, gradient: from 5% to 50% of A in 15 min,
ﬂow: 5 mL/min, tR = 10.8 min) and lyophilized to give
compound 7 as a white powder (17 mg, quantitative yield). 1H
NMR (400 MHz, D2O): δ = 4.70−4.61 (m, 3H), 4.52 (t, J =
7.1 Hz, 1H), 4.46−4.38 (m, 2H), 4.31 (dd, J = 8.7, 5.5 Hz, 1H),
4.20 (d, J = 16.4 Hz, 1H), 3.96 (d, J = 17.2 Hz, 1H), 3.89 (d, J
= 17.3 Hz, 1H), 3.73 (d, J = 16.3 Hz, 1H), 3.38−3.09 (m, 9H),
3.01 (dd, J = 13.0, 4.9 Hz, 1H), 2.93 (dd, J = 15.5, 6.5 Hz, 1H),
2.83−2.70 (m, 2H), 2.27 (t, J = 7.1 Hz, 2H), 2.06 (s, 3H),
1.95−1.36 (m, 16H). 13C NMR (101 MHz, D2O): δ = 176.63,
174.66, 174.27, 174.25, 173.90, 173.59, 172.11, 171.89, 171.79,
171.44, 165.30, 156.71, 62.10, 60.25, 55.46, 54.03, 53.45, 53.42,
53.20, 50.50, 42.76, 42.03, 40.99, 40.53, 40.33, 39.70, 38.92,
35.64, 35.46, 30.33, 27.87, 27.80, 27.67, 27.51, 25.17, 24.40,
22.45, 21.73. MS (ESI, m/z): calculated for C38H63N15O11S3
1001.4; found 1002.4 [M + H]+. RP-HPLC: solvent A: CH3CN
0.1% TFA, Solvent B: H2O 0.1% TFA, gradient: from 5% to
50% of A in 15 min, tR = 10.5 min, ﬂow: 1 mL/min, λ = 220
nm.
Synthesis of 5(6)-Carboxy-2′,7′-diﬂuoroﬂuorescein
(Oregon green 488).19 Trimetillic anhydride (750 mg, 3.9
mmol, 1 equiv) was added to a 1 M solution of 4-
Fluororesorcinol (1 g, 7.8 mmol, 2 equiv) in methanesulfonic
acid (7.8 mL). The resulting mixture was heated under dry
nitrogen at 80 °C for 24 h. The cooled mixture was poured into
7 volumes of ice water and the resulting precipitate was
ﬁltrated, washed with H2O, and dried at 60 °C to give 5(6)-
carboxy-2′,7′-diﬂuoroﬂuorescein as an orange powder (1.6 g,
quantitative yield). 1H NMR (400 MHz, MeOD) δ 8.64 (s,
1H), 8.42 (dd, J = 8.0, 1.5 Hz, 1H), 8.35 (dd, J = 8.0, 1.3 Hz,
1H), 8.14 (d, J = 7.7 Hz, 1H), 7.79 (s, 1H), 7.36 (d, J = 8.0 Hz,
1H), 6.90−6.85 (m, 4H), 6.46 (d, J = 10.2 Hz, 4H). 19F NMR
(376 MHz, DMSO-d6) δ −139.69, −139.73.
Synthesis of cCNGRCKG-OG 8. NovaPEG Rink Amide
resin (1.0 g, 0.49 mmol, loading: 0.49 mmol/g) was used for
the synthesis of the linear peptide 11. Swelling, Fmoc cleavage,
and washing of the resin were performed as described for
compound 2. The coupling reaction was performed by adding
to the resin a solution of the Fmoc-aa (2.45 mmol, 5 equiv),
HATU (913 mg, 2.4 mmol, 4.9 equiv), DIPEA (0.8 mL, 4.9
mmol, 10 equiv) in DMF (5 mL), and the mixture was shaken
for 2 h. The amino acid coupling sequence was Fmoc-Gly-OH,
Fmoc-Lys(Dde)-OH, Fmoc-Cys(Mmt)-OH, Fmoc-Arg(Pbf)-
OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Boc-Cys(Mmt)-OH.
After assembling the linear peptide, the Dde removal was
achieved as described for compound 6 and the ﬂuorescent
probe OG (synthesized as a mixture of 5 and 6 regioisomers
according to ref 19) was then coupled by adding to the resin
the solution of OG (400 mg, 0.98 mmol, 2 equiv), HATU (365
mg; 0.96 mmol, 1.96 equiv), and DIPEA (0.33 mL, 1.96 mmol,
4 equiv) in DMF (6 mL) and the resulting red suspension was
shaken for 2 h. The resin was extensively washed with DMF (3
× 5 mL), DCM (3 × 5 mL), and MeOH containing 0.1%
NH4OH conc. (10 × 5 mL). Cleavage of the OG labeled
peptide 13 from the resin and simultaneous removal of Mmt,
Trt, and Pbf protecting groups were performed using a mixture
of TFA/TIPS/H2O 95:2.5:2.5 v/v/v for 2 h. The mixture was
concentrated and Et2O was added to precipitate the crude
peptide. N-Chlorosuccinimide (53 mg, 0.4 mmol, 1 equiv) was
added to the solution of the crude linear peptide (540 mg, TFA
salt, 0.4 mmol, 1 equiv) in H2O/CH3CN 9:1 (40 mL) and the
reaction was allowed to stir at room temperature for 15 min.
The reaction mixture was then frozen in dry ice and freeze−
dried to obtain the crude cyclic peptide as an orange powder.
The crude peptide was puriﬁed by semipreparative RP-HPLC
(Solvent A: CH3CN 0.1% TFA, Solvent B: H2O 0.1% TFA,
gradient: 26% of A in 7 min, ﬂow: 5 mL/min, isomer A, tR = 5.6
min; isomer B, tR = 6.1 min) and lyophilized to give compound
8 isomer A and isomer B as an orange powder (180 mg, TFA
salt, 25% yield based on the estimated loading of the resin).
Isomer (A): 1H NMR (400 MHz, D2O) δ = 8.45 (s, 1H),
8.10−8.03 (m, 1H), 7.34−7.25 (m, 1H), 6.82−6.75 (m, 2H),
6.67−6.56 (m, 2H), 4.91 (t, J = 7.1 Hz, 1H), 4.60 (dd, J = 8.9,
2.8 Hz, 1H), 4.40−4.31 (m, 1H), 4.26−4.16 (m, 2H), 4.11 (d, J
= 15.8 Hz, 1H), 3.95 (d, J = 17.6 Hz, 1H), 3.88 (d, J = 17.2 Hz,
1H), 3.65 (d, J = 15.6 Hz, 1H), 3.47−2.98 (m, 8H), 2.83 (dd, J
= 15.3, 6.3 Hz, 1H), 2.73 (dd, J = 15.5, 7.7 Hz, 1H), 1.98−
−1.36 (m, 10H). 19F NMR (376 MHz, D2O) δ = −75.55 (TFA
signal), −134.87. Isomer (B): 1H NMR (400 MHz, D2O) δ =
8.10 (d, J = 6.8 Hz, 1H), 7.96 (d, J = 6.5 Hz, 1H), 7.54 (s, 1H),
6.80−6.77 (m, 2H), 6.56 (s, 2H), 4.91 (t, J = 7.1 Hz, 1H), 4.58
(dd, J = 9.1, 3.6 Hz, 1H), 4.27−4.16 (m, 3H), 4.11 (d, J = 15.7
Hz, 1H), 3.91 (d, J = 17.2 Hz, 1H), 3.84 (d, J = 17.2 Hz, 1H),
3.65 (d, J = 15.7 Hz, 1H), 3.40−2.98 (m, 8H), 2.84 (dd, J =
15.6, 6.4 Hz, 1H), 2.73 (dd, J = 15.5, 7.8 Hz, 1H), 1.82−1.26
(m, 10H). 19F NMR (376 MHz, D2O) δ = −75.55 (TFA
signal), −134.87. MS (ESI, m/z): calculated for
C47H55F2N13O14S2 1127.3; found 1128.4 [M + H]
+. RP-
HPLC: solvent A: CH3CN 0.1% TFA, Solvent B: H2O 0.1%
TFA, gradient: from 10% to 60% of A in 15 min, isomer A, tR =
9.9 min; isomer B, tR = 10.2 min, ﬂow: 1 mL/min, λ = 480 nm.
In Vitro APN Inhibition Assay. IC50 values against APN
were determined as previously described12,20,21 using L-leucine-
p-nitroanilide as substrate and microsomal aminopeptidase
from porcine kidney (pAPN, Sigma) (15 units/mg protein).
The assay was performed in a 96-well plate in Phosphate Buﬀer
Saline (PBS, KH2PO4 1.47 mM, Na2HPO4 7.8 mM, NaCl 137
mM, KCl 2.7 mM, CaCl2 1.8 mM, MgCl2 1.8 mM), pH 7.2, at
37 °C. Bestatin was used as a positive control, while biotin was
used as a negative one. 0.5 μg/mL pAPN and 250 μM L-
leucine-p-nitroanilide were incubated in 100 μL of PBS, pH 7.2
in the presence of gradient concentrations of inhibitor (the
concentration of peptides 2−7 and biotin ranged from 5 μM to
2.5 mM, while the concentration of bestatin 1 from 50 nM to
25 μM). The assay mixture was incubated at 37 °C for 1 h.
Formation of the product p-nitroaniline was monitored by
following the change in the absorbance measured at 405 nm
with the UV−vis spectrophotometer (Synergy HT, BioTek).
The IC50 value was deﬁned as the concentration of each
peptide that led to 50% of maximal pAPN catalytic activity.
Cell Culture. Human ﬁbrosarcoma HT1080 cells were
cultured in Dulbecco’s Modiﬁed Essential Medium (Invitro-
gen) containing 9% fetal bovine serum (SIGMA) and incubated
at 37 °C in a humidiﬁed atmosphere containing 5% CO2 and
passed twice a week.
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Inhibitory Assay on HT1080 Cells. One day prior to the
experiment, HT1080 cells from a conﬂuent plate were detached
using trypsin/EDTA (Invitrogen) and plated at a 70%
conﬂuency in 96 well plate (approximately 60 000 cell/well).
24 h later the cells were washed twice in PBS and incubated in
100 μL of PBS containing 250 μM APN substrate (L-leucine-p-
nitroanilide) and the diﬀerent compounds at the indicated
concentration. The cells were then incubated for 1.5 h at 37 °C
and absorbance at 405 nm measured every 10 min.
Binding Curve of Fluorescent cCNGRCKG-OG 8 on
HT1080 Cells. One day prior to the experiment, HT1080 cells
from a conﬂuent plate were detached using trypsin/EDTA
(Invitrogen) and plated at a 20% conﬂuency in 96 well plate
(approximately 20 000 cell/well). After 24 h the cells were
incubated for 60 min on ice with increasing concentration of
compound 8. After incubation the cells were washed three
times in PBS and ﬁxed in paraformaldehyde (3.7% in PBS) for
15 min, washed three times in PBS, and imaged at 20×
magniﬁcation. For each ﬁeld both a DIC and a ﬂuorescent
channel were collected.
Displacement of Fluorescent cCNGRCKG-OG 8 on
HT1080 Cells. One day prior to the experiment, HT1080 cells
from a conﬂuent plate were detached using trypsin/EDTA
(Invitrogen) and plated at a 20% conﬂuency on glass coverslips
(approximately 20 000 cell/well). After 24 h the cells were
incubated for 60 min on ice with compound 8 (40 μM) in the
absence or in the presence of bestatin (100 μM) or compound
6 (1 mM). After incubation the cells were washed three times
in PBS and ﬁxed in paraformaldehyde (3.7% in PBS) for 15
min, washed three times in PBS, and imaged at 40×
magniﬁcation. For each ﬁeld both a DIC and a ﬂuorescent
channel were collected.
Quantiﬁcation of Fluorescence on Cells. The micro-
scopic ﬁelds were acquired using the same settings and
exposure time for all the images and we ensured that all the
pixels in the images were in the dynamic range of the detector
(saturated pixels <0.1%). The images were then analyzed using
ImageJ open source software. The outline of the cells were
manually traced using the DIC channel. The outlines of the
cells were then superimposed to the ﬂuorescent channel and
the ﬂuorescence of each single cell was measured. For each
condition we measured at least 120 cells.
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